Clinlogix, a privately held and globally active clinical research organisation (CRO) based in the US, has beefed up its presence in the European market by acquiring Germany’s ikfe CRO for an undisclosed sum.
Ikfe CRO’s origins go back to September 2008, when Professor Dr Andreas Pfützner set up the Institute for Clinical Research and Development (ikfe GmbH) in Mainz, Germany, with divisions for laboratory testing and clinical research. ikfe CRO was spun off as an independent company in September 2008.
According to Dr Marco Grenningloh, chief operating officer and managing director of Clinlogix Europe, acquiring ikfe “greatly strengthens our strategic resources, knowledge base and infrastructure in the largest pharmaceutical market in the world”.
Grenningloh described ikfe CRO as a “highly respected regional service provider” whose specialised expertise and in-depth understanding would further enhance Clinlogix’s capacity to provide knowledgeable, high-quality services to clients around the globe.
Clinlogix Europe will operate from its base in Germany as a full-service clinical-research organisation supporting the development of drugs, devices and diagnostics over a range of therapeutic areas, but with particular expertise in diabetes, cardiovascular disease and oncology.
Tailored solutions
The parent company has been offering tailored clinical-research solutions to the biopharmaceutical and medical device industries for nearly 25 years.
The Clinlogix service portfolio spans the whole product-development cycle, from early feasibility/discovery through to first-in-human studies, feasibility, pivotal and post-marketing clinical studies, as well as expertise in regional and worldwide regulatory requirements.
“Our flexible business model focuses on innovation, integration and execution to drive operational excellence and efficiency,” noted chief executive officer JeanMarie Markham. “It has supported our rapid growth in the US, Latin America and now Europe.”
ikfe CRO is a “high quality acquisition that provides us with the personnel, relationships and infrastructure to bring our unique service mix to clients on a worldwide basis”, Markham added.
